Alembic Pharma Eyes FY26 Growth with Domestic Surge and Global Push

Alembic Pharmaceuticals has raised its expectation margin for FY26, with increased domestic sales, and international expansion. The CFO of the company, R.K.Baheti informed Moneycontrol that the company recorded higher EBITDA of 16 percent margins for FY25. This result has been derived after better capacity utilization and significantly reduced Capex. R&D investments of the company are said to be sustained at 7-8 percent of revenue, mainly focusing on oncology, injectables, peptides and GLP-1 products.

For Q4FY25, Alembic reported a 17% YoY revenue rise to ?1,770 crore, with EBITDA at ?286 crore (up 9% YoY) and net profit at ?157 crore (down 12% YoY). FY25 revenue rose 7.1% to ?6,672 crore, while net profit dipped 5.2% to ?584 crore.

Alembic is expecting volume recovery amid easing inflation. The company will be capitalizing on patent expiries in cardiovascular, gastro, and gynecology segments. The firm ranks 20th in the Indian Pharma Market, with over 5,500 reps and four ?100+ crore brands. Animal health grew 19% in FY25 amid easing inflation. Alembic will capitalize on patent expiries in cardiovascular, gastro, and gynecology segments. The firm ranks 20th in the Indian Pharma Market, with over 5,500 reps and four ?100+ crore brands. Animal health grew 19% in FY25

Despite U.S. generic price erosion, the U.S. contributed ?1,957 crore (27% of revenue) with 13.1% growth. Alembic plans 20 product launches in FY26, including day-one and limited-competition drugs, targeting 15%+ growth in the U.S. Mr. Baheti stated, "Unfortunately, price erosion despite all our expectations that they have come to a level where further erosion may be limited, etc., etc., but price erosion continues." The API segment, 17% of revenues, rebounded in Q4 after a 9.1% YoY decline. Alembic is closely monitoring China’s market behavior amid potential U.S. barriers. Non-U.S. markets like Canada, Australia, Europe, and Latin America are strategic growth areas, supported by new capacities and USFDA-approved facilities.